



Published in final edited form as:

Dev Biol. 2013 February 15; 374(2): 255–263. doi:10.1016/j.ydbio.2012.12.009.

Elk3 is essential for the progression from progenitor to definitive neural crest cell

Crystal D. Rogers, Jacquelyn L. Phillips, and Marianne E. Bronner

Division of Biology 139-74, California Institute of Technology, Pasadena, CA 91125

Abstract

Elk3/Net/Sap2 (here referred to as *Elk3*) is an Ets ternary complex transcriptional repressor known for its involvement in angiogenesis during embryonic development. Although *Elk3* is expressed in various tissues, additional roles for the protein outside of vasculature development have yet to be reported. Here, we characterize the early spatiotemporal expression pattern of *Elk3* in the avian embryo using whole mount in situ hybridization and quantitative RT-PCR and examine the effects of its loss of function on neural crest development. At early stages, *Elk3* is expressed in the head folds, head mesenchyme, intersomitic vessels, and migratory cranial neural crest (NC) cells. Loss of the *Elk3* protein results in the retention of Pax7+ precursors in the dorsal neural tube that fail to upregulate neural crest specifier genes, *FoxD3*, *Sox10* and *Snail2*, resulting in embryos with severe migration defects. The results putatively place *Elk3* downstream of neural plate border genes, but upstream of neural crest specifier genes in the neural crest gene regulatory network (NC-GRN), suggesting that it is critical for the progression from progenitor to definitive neural crest cell.

Keywords

Elk3; Neural crest specification; Progenitors; Pax7

Introduction

Neural crest (NC) cells are a transitory and vertebrate-specific cell type that are induced at the border of the neural plate and the non-neural ectoderm, and subsequently come to reside within the neural folds during neurulation. After neural tube closure, these cells delaminate from the neuroepithelium and migrate to distant locations in the embryo where they differentiate into multiple derivatives, including craniofacial cartilage and bone, neurons and glia of the peripheral nervous system, and melanocytes (Rogers et al., 2012). These cells are unique and interesting because they resemble stem cells in their ability to form multiple derivatives, as well as metastatic cancer cells in their ability to migrate and invade different tissues. Abnormal NC development can result in defective embryogenesis leading to birth defects.

A proposed neural crest gene regulatory network (NC-GRN) helps to explain some of the molecular interactions that are involved in neural crest cell specification, and their subsequent epithelial to mesenchymal transition (EMT) that leads to the formation of the

© 2012 Elsevier Inc. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

migratory population (Sauka-Spengler and Bronner-Fraser, 2008). An important goal in the neural crest field is to identify additional factors that are involved in the NC-GRN, and to test their possible developmental roles. To aid in this goal, we previously conducted screens for genes that are upregulated during the process of neural crest formation (Adams et al., 2008; Gammill and Bronner-Fraser, 2002). Several transcription factors were identified that had not previously been known to function in the neural crest.

One of the genes upregulated as a consequence of neural crest induction is Elk3/Net/Sap2 (referred to hereafter as Elk3), a ternary complex factor that belongs to the Ets family of transcription factors. Elk3 is a transcriptional repressor that has been linked to cancer metastasis (Li et al., 2008; Sloan et al., 2009), wound healing, and vasculogenesis in cell lines and in mice (Ayadi et al., 2001b; Nozaki et al., 1996; Zheng et al., 2003). However, little is known about its role in normal embryonic development, although in vitro studies have suggested a role in cell migration (Buchwalter et al., 2005). *Elk3* is expressed in the developing vasculature, the cranial mesenchyme and the limb buds of mouse embryos (Ayadi et al., 2001b). In addition, in vivo studies of the function of Elk3 during tumorigenesis in mice showed that individuals lacking Elk3 protein had smaller tumors due to their inability to become vascularized and oxygenated (Zheng et al., 2003).

Although well studied in vitro as a ternary complex factor, little is known about the function of Elk3 during early embryonic development. Here, we describe the spatiotemporal expression pattern and function of Elk3 during avian embryogenesis. In addition to its previously known distribution in the vasculature, we report that *Elk3* is expressed in the neural folds and migratory cranial neural crest. The results show that loss of the Elk3 protein prevents proper neural crest specification, inhibits migration and results in the retention of precursor cells in the dorsal neural tube. Thus, in addition to its role in the vascular system, Elk3 also plays a critical role in neural crest development.

Materials and Methods

Embryos

Fertilized chicken eggs were obtained from local commercial sources (McIntyre Farms, San Diego, CA) and incubated at 37°C to the desired stages according to the criteria of Hamburger and Hamilton (HH). For whole mount in situ hybridization (WISH), embryos were fixed for one hour to overnight in 4% paraformaldehyde (PFA) at room temperature or 4°C, respectively, washed in PTW (PBS containing 0.1% Tween) and dehydrated in MeOH at room temperature before being stored at -20°C in 100% MeOH.

RNA Preparation and quantitative PCR

RNA was prepared from embryos (n = 10) using the RNeasy-Micro isolation kit (Qiagen) following the manufacturer's instructions. The obtained RNA was treated with DNaseI amplification grade (Invitrogen) and then reverse-transcribed to cDNA with SuperScript II (Invitrogen) using random hexamers. QPCR was performed using the 96-well plate ABI 7000 QPCR machine with SybrGreen Itaq Supermix with ROX (Bio-Rad), 150–450 nM of each primer, and 200–500 ng of cDNA in a 25 µl reaction volume. During the exponential phase of the QPCR reaction, a threshold cycle (CT) and baseline was set according to the protocols of Applied Biosystems. The results for different samples were then analyzed using the Livak/ $\Delta\Delta C_t$ method. There were three replicates for every sample and GAPDH was used as a control.

Electroporation of Antisense Morpholinos and DNA Vectors

Two translation blocking antisense morpholinos to Elk3 (E3MO) were designed: E3MO1: 5'-TGTTTCAGAGGGAGCTGGGTAAAACC-3', E3MO2: 5'-TGATTGCACTCTCCATACCCAGAGC-3' and one control morpholino (ContMO) was used: 5'-CCTCTTACCTCAGTTACAATTTATA-3'. Injections of the fluorescein-tagged morpholino (1–3 mM plus 0.5–1.5 mg/ml of PCI carrier plasmid DNA) (Voiculescu et al., 2008) were performed by air pressure using a glass micropipette targeted to the presumptive neural crest region at HH stages 4–5. Rescue experiments were performed in the same manner as E3MO electroporations except that the PCI-Elk3-RFP plasmid was used (.75 mg/ml) instead of the PCI carrier plasmid. Stage 4–5 electroporations were conducted on whole chick embryo explants placed ventral side up on filter paper rings. The Elk3 morpholinos and vectors were injected on the right side of the embryo, and the controls were injected on the left side when co-injected, and platinum electrodes were placed vertically across the chick embryos and electroporated with five pulses of 6.3 V in 50 ms at 100 ms intervals. The embryos were cultured in 1.0 ml of albumen in petri dishes until they reached the desired stages. The embryos were then removed and fixed for one hour to overnight in 4% PFA at room temperature or 4°C, respectively. The embryos were placed in PTW, viewed and photographed as whole mounts using a fluorescence stereomicroscope to show the electroporation efficiency.

Whole Mount In Situ Hybridization (WISH)

Chick WISH was performed as previously described (Acloque et al., 2008) with the following modifications: embryos were not treated with proteinase K, triethanolamine, or acetic anhydride, on day one, and the day two washes were shortened, no CHAPS was used and MABT was used instead of KTBT. The linearized plasmid DNA templates that were used for digoxigenin- and fluorescein-labeled RNA probes were *Elk3*, *FoxD3*, *Sox10*, *Snail2* and *Sox2*. The embryos were imaged in whole mount and after were transverse sectioned at 14–25 µm in a Microm HM 550 cryostat.

Immunohistochemistry

Immunohistochemistry for Pax7 (Developmental Studies Hybridoma Bank (DSHB), Pax7), HNK1 (DSHB, 3H5), Snail2 (DSHB, 62.1E6), Sox2 (R&D Systems, AF-2018), Pax6 (Covance, PRB-2184), Caspase (R&D Systems, AF835) and PH3 (Upstate/Millipore, 06-570) was performed as follows. Embryos were fixed in 4% paraformaldehyde in phosphate buffer for twenty minutes at room temperature. All washes were performed in TBST + Ca²⁺ with .5% triton x-100. Blocking was performed with 10% donkey serum in the same buffer. The primary antibodies (1:10 for all hybridoma antibodies and 1:1000 for all others) were incubated in the TBST buffer from overnight to two days at 4° and secondary antibodies (1:500 to 1:1000) were applied in the same buffer for either three hours at room temperature or overnight at 4°.

Cell Death and Proliferation

Embryos were immunostained with the proliferation marker phosphorylated histone H3 (rabbit anti-PH3 IgG, 1:1000) or the apoptosis marker, caspase (rabbit anti-caspase IgG, 1:1000), and then detected using the secondary Alexa Fluor goat anti-rabbit 350 (1:1000).

Results

Sequence of chick Elk3 protein

The chick Elk3 protein is highly conserved with human, mouse and zebrafish (Fig. 1A), exhibiting an overall amino acid sequence similarity of 86%-88% with mouse and human,

respectively, 60% similarity with zebrafish and approximately 98% conservation in the functional domains between organisms. The chick *Elk3* protein contains an Ets binding domain (amino acid (a.a.) residues 1–89), a serum response factor interaction domain (a.a. 141–162), two repressor domains (a.a. 166–176, 283–293), a mitogen activated protein (MAP) kinase docking site (a.a. 299–302) and a MAP kinase transcriptional activation site (a.a. 335–388).

Expression of *Elk3* in the chick embryo

Using in situ hybridization to visualize the spatiotemporal expression pattern of transcripts, the *Elk3* expression pattern appears very dynamic throughout the early stages of chick development. *Elk3* is expressed in the anterior primitive streak by Hamburger-Hamilton (HH) stage 4 (Fig. 1B) and in the developing head folds and head mesenchyme at HH8 (Fig. 1C, 1C'). *Elk3* is expressed at low levels in the early neural folds (Fig. 1C'), and transcript levels appear to decrease around the time of neural tube closure. At HH9, *Elk3* remains in the developing head mesenchyme (Fig. 1D), which will eventually contribute to portions of the craniofacial bone, vasculature and muscle populations. *Elk3* transcripts then appear to be elevated in a subpopulation of migrating cranial NC cells at HH10–11, as well as in the R4 migratory stream and the cranial mesenchyme (Fig. 1E, 1E'). *Elk3* transcripts partially overlap with the migratory neural crest cell marker, HNK1 (Fig. 1E', green), and with *Pax7* in the migratory crest (Fig. 1E', red), but are below the level of detection by in situ hybridization in the dorsal neural tube (Fig. 1E'). By HH stage 20, *Elk3* is expressed in the developing limb buds, the branchial arches, and the intersomitic blood vessels (Fig. 1F) similar to the patterns described in mouse embryos (Ayadi et al., 2001a).

To determine the quantitative expression levels of *Elk3*, we performed quantitative PCR (QPCR) on 10 whole embryos from stages HH4–HH11. When normalized to *GAPDH* expression and compared to the *Elk3* expression levels at HH4 using the Livak/ $\Delta\Delta C_t$ method, *Elk3* appears to be expressed at low levels through stages HH4–6, and the expression increases at HH7 just prior to the onset of neural crest specifiers like *FoxD3* and *Snail2*. The expression peaks between stages HH8–11, as neural crest cells commence migration, and levels remain high as development proceeds (Fig. 1G).

Elk3 is required for cranial NC specification

Because *Elk3* is expressed in the developing head folds beginning at HH7, we blocked the expression of the *Elk3* protein during gastrulation at HH4 by electroporating one of two translation blocking morpholinos, referred to throughout as “E3MO”, prior to the onset of *Elk3* expression in the neural folds. To examine the effects of *Elk3* knockdown on cranial NC specification, we performed whole mount in situ hybridization (WISH) for the neural crest specifier genes, *FoxD3* and *Sox10* (Figure 2A–2E). Loss of the *Elk3* protein greatly reduced the number of *FoxD3*-expressing cells on the injected side of the embryo at HH8 (Fig. 2A, arrow, N= 11/14), consistent with a requirement for *Elk3* in cranial NC specification. In addition, the expression of *Sox10* was greatly reduced on the *Elk3*-morphant side of the embryo at the same stage (Fig. 2C, arrow, N= 9/10). In transverse section, only cells lacking E3MO are seen to express *Sox10* (Fig. 2E). Overexpression of the pCI-RFP-*Elk3* DNA construct in concert with E3MO at HH4 was sufficient to rescue the expression of both *FoxD3* and *Sox10* at HH8 (Fig. 2B, 2D, N= 6/8 and 10/14, respectively), demonstrating the specificity of the effect. In addition, we examined *Snail2* protein expression which, similar to *FoxD3* and *Sox10*, was reduced at HH9 after *Elk3* knockdown (Fig. 2F, 2F', arrow, N= 15/16).

The effects of *Elk3*-knockdown on the neural crest specifier genes, *FoxD3*, *Sox10*, and *Snail2* prompted us to examine the requirement of *Elk3* for the expression of the neural plate

border gene, *Pax7*, which is required for neural crest formation during gastrulation and lies upstream of neural crest specifier genes in the neural crest gene regulatory network (Basch et al., 2006; Betancur et al., 2010). During normal development, *Pax7* is expressed in the newly induced crest population residing in the neural folds and is also expressed by migratory neural crest cells. Therefore, *Pax7* represents a good marker for assessing whether *Elk3* is required for maintenance of the neural crest precursor pool. Surprisingly, we noted that the loss of *Elk3* resulted in a maintenance or increase of *Pax7* protein in dorsal neural tube cells (Fig. 2G, 2G', asterisk, N= 13/14) concomitant with the loss of *FoxD3* and *Sox10*. Sections of an HH8–9 embryo immunostained for *Pax7* expression show that *Pax7* levels are unaffected in the presumptive midbrain at this stage (Fig. 2G', asterisk), and may be increased in more posterior and “younger” dorsal neural tube cells (data not shown). This phenotype is consistent with the possibility that *Elk3* may be required for the transition of NC precursors to NC cells, and that the loss of *Elk3* maintains newly induced precursors in a “stem-like” state prior to the onset of definitive neural crest markers.

Since the loss of *Elk3* led to a decrease in NC cell specifier genes and a maintenance or upregulation of *Pax7*, we examined whether the addition of exogenous *Elk3* had an effect on neural crest specification. To this end, we electroporated an overexpression construct (pCI-*Elk3*-RFP, here referred to as “*Elk3*”) at HH4. The results suggest that *Elk3* overexpression reduces the numbers of migratory *Snail2*⁺ neural crest cells while causing a minor upregulation of *Snail* in the premigratory neural crest (Fig. 2H, 2H', N= 6/8). *Pax7* appeared to be slightly decreased in a subset of the embryos (Fig. 2I, 2I', N= 4/7) on the *Elk3*-injected side. The results suggest that over-expression of *Elk3* can effect neural crest development, though not exactly opposite to that of its knock-down. These data are consistent with the possibility that maintenance of appropriate levels of this transcription factor in the neural crest is critical.

To determine when *Elk3* activity is required during neural crest specification, we electroporated the E3MO from stages HH4– HH8. *Elk3* knockdown between stages HH4–HH6 yielded similar results to those described in previous experiments; *Sox10* expression and neural crest migration were reduced at both stages (Fig. 3A–3B, 3E–3F, N= 16/20). When the E3MO was electroporated at HH5, *Pax7* and *HNK1* expression were lost in migratory neural crest cells similar to effects of electroporations at HH4 (Fig. 3E, 3E' compared to Fig. 2G, 2G', N= 4/5). Electroporations performed at HH6 also affected *Pax7* and *HNK1* expression in migratory cells, but to a lesser extent (Fig. 3F, F', N= 5/6). Thereafter, the effects were less penetrant with embryos appearing morphologically normal at stages 7/8 (Fig. 3C– 3D, 3G, N= 8/8), but somewhat delayed neural crest migration that was only detectable after sectioning (Fig. 3G', arrow).

To determine if the reduction of *FoxD3* and *Sox10* expression was due to a decrease in proliferation or an increase in cell death, we performed immunohistochemistry using a proliferation marker, phosphorylated histone H3 (PH3), and a marker of apoptosis, caspase, after knockdown of *Elk3* using the E3MO. The results show that loss of the *Elk3* protein had little effect on proliferation as evidenced by similar levels of PH3 on the injected and uninjected internal control side in both the whole mount and section (Fig. S1A, S1C–D, N= 9/11). This suggests that the loss of specifier genes is not due to a lack of proliferation. However, knocking down *Elk3* at HH4 did cause a slight increase in cell death mainly localized to the ventral neural tissue (Fig. S1B, S1E, N= 12/15). Curiously, the ventral neural tube lacks *Elk3* expression suggesting that this affect may be non-cell autonomous. In addition, we examined the effects of *Elk3*-RFP overexpression to determine if it is sufficient to induce cell proliferation or if excess *Elk3* affects cell death. Overexpression of *Elk3* had little effect on PH3 (Fig. S1F, S1H, N= 6/6) or caspase (Fig. S1G, S1I, N=4/4) expression when compared to the control (RFP, left side).

Elk3 is not required for neural development

The neural plate border region can give rise to either neural crest or dorsal neural tube cells, which become part of the CNS (Krispin et al., 2010). Therefore, to verify that the loss of the neural crest specifier expression that was observed after Elk3 knockdown was not due to the inhibition of neural development, we electroporated the E3MO into HH4 embryos and performed WISH for the neural gene, *Sox2*, and performed immunohistochemistry for *Sox2* and *Pax6* proteins, both of which mark neural cells. The loss of Elk3 did not affect the expression of *Sox2* (Fig. 4A, N= 5/6) when compared to the ContMO (Fig. 4B). In addition, immunohistochemistry for *Sox2* (neural progenitors) and *Pax6* (neural and ectodermal tissues) proteins, showed that there is no decrease in the expression of either *Sox2* (Fig. 4C, 4C', N= 12/13) or *Pax6* (Fig. 4D, 4D', N= 10/10) in the neural tube, and the ectoderm marked by *Pax6* is unaffected in the Elk3-morphant cells (Fig. 4D'). Additional experiments were performed to determine if Elk3 overexpression affected neural development. Embryos injected with RFP (left side) and Elk3 (right side) had little change in *Sox2* protein expression (Fig. 4E, 4E', N= 4/4). These data support a role for Elk3 specifically in the development of cranial NC cells independent of non-NC ectodermal derivatives.

Elk3 knockdown reduces cranial NC migratory streams and anterior cranial structures

Although Elk3 plays a clear role in cranial NC cell specification, the *Elk3* transcript is also expressed in migratory cranial NC cells. To examine if Elk3 is required for EMT or migration, we electroporated E3MO into HH4 embryos and performed WISH for *Sox10* (Fig. 5A–5B) and *Snail2* (Fig. 5C–5D) expression at migratory stages. The results show that loss of Elk3 has a dose dependent effect on both *Sox10* (N= 17/22) and *Snail2* (N= 9/12) expression in the migratory crest. At 1.5 mM, the E3MO reduces the migratory field marked by both *Sox10* and *Snail2* in stage HH9–HH10 embryos (Fig. 5A, 5C). At 3mM, the cranial NCs expressing *Sox10* and *Snail2* appeared to be even more reduced (Fig. 5B, 5D). We performed immunohistochemistry with the HNK1 antibody, which labels migrating neural crest cells, and observed a profound decrease in the HNK1 positive cells as well as the distance traveled by these cells on the E3MO-injected side compared to the control MO injected side (Fig. 5E, compare right side with left side, N= 11/11). Despite the reduction in *Sox10*, *Snail2* and HNK1-positive migratory cells, prominent *Pax7*-expressing cells remained in the dorsal neural tube at HH9 (Fig. 5F, N= 9/9). In fact, the only *Pax7*-positive migratory cells are E3MO negative and hence are able to migrate laterally at HH10 (Fig. 5G) whereas the *Pax7*⁺/E3MO⁺ cells remain in the dorsal neural tube. These data support a role for Elk3 in the transition from *Pax7*-positive progenitor cells at the onset of NC cell specification to *FoxD3*/*Snail2*/*Sox10*-positive cells that form bona fide migratory neural crest cells.

To determine if the effects of Elk3 knockdown recovered over time, E3MO-electroporated embryos were allowed to survive until 2–3 days post-electroporation (HH16–17). In all cases (n=7), the embryos exhibited severe anterioposterior head axis shortening (Fig. S2, asterisks) and craniofacial defects characterized by the loss of the most anterior structures, like the olfactory placode, a posterior to anterior shift of the eyes, and more dispersed and anteriorly-localized *Sox10*⁺ neural crest cells. In addition, the embryos exhibited abnormal branchial arch development, lack of trigeminal ganglion development and a failure to close the frontonasal process (Fig. S2, arrow). All embryos also had posterior blood vessel edema and heart developmental defects when compared to uninjected controls (data not shown). Thus, they failed to recover from the early specification and migratory effects after loss of Elk3.

Discussion

Elk3 is known to function as a transcriptional repressor that is required for wound healing, tumor growth and angiogenesis in mouse models, and also functions as an anti-oncogenic factor in some cancers (Li et al., 2008; Nakade et al., 2004; Zheng et al., 2003). Here, we show that during development, *Elk3* is expressed in the cranial mesenchyme and the neural folds at the onset of neural crest specification as well as in migratory crest cells at later stages. Based on its conserved expression pattern in chick (Fig. 1B), mouse (Ayadi et al., 2001a), and frog (Bowes et al., 2010), together with high conservation in functional domains (98%) across species (Fig. 1A), we speculate that Elk3 may play a conserved role during vertebrate neural crest development.

Loss of function experiments demonstrate that Elk3 is critical for normal neural crest development. The results show that Elk3 is required for the expression of the neural crest specifier genes *FoxD3*, *Sox10* and *Snail2* (Fig. 2), and that its knockdown leads to a loss of migratory neural crest cells (Fig. 5) and later to abnormal craniofacial development (Fig. S2). Interestingly, Elk3-morphant cells in the dorsal neural tube maintain expression of Pax7 protein (Fig. 2G–2J, Fig. 5F, 5G). These cells are unable to upregulate *FoxD3*, *Sox10* and *Snail2* (Fig. 2A–2F), or to migrate out of the neural tube (Fig. 3, 5), whereas neural development proceeds normally (Fig. 4).

These results raise the intriguing possibility that cells receiving the E3MO may be arrested in a progenitor or stem-cell like stage prior to the expression of bona fide neural crest markers, like *Sox10*, *Snail2* and *FoxD3*, suggesting that Elk3 may be a prerequisite for their subsequent expression. After Elk3 knock-down, the cells are maintained in a Pax7+ but bona fide neural crest marker negative state, which we speculate represents a “progenitor” state. Although there is an apparent reduction in *Elk3* transcript levels around the time of neural tube closure, we cannot rule out the possibility that even low levels of transcript, perhaps below the level easily detectable by in situ hybridization, still produce enough protein to have a critical effect on downstream genes. In the context of the cranial neural crest gene regulatory network, this places Elk3 in a critical position between neural plate border and neural crest specifier genes, functioning downstream of the former, but upstream of the latter. Taken together, the results reveal a novel developmental role for Elk3 in neural crest cell specification, outside of its known roles in angiogenesis and cancer progression.

The neural plate border gene, *Pax7*, is required during gastrulation for NC cell fate specification in chicken (Basch et al., 2006) and later in development, Pax7-positive cells contribute to NC cell derivatives (Murdoch et al., 2012). However, Pax7-null mice exhibit very mild NC-related defects, but die soon after birth (Mansouri et al., 1996). Mansouri et al. (1996) suggest that in the mouse, Pax7 and its paralog, Pax3, may compensate for the loss of one another. In contrast, at early stages of chick development, Pax7 appears to be the dominant paralog since it is expressed earlier than Pax3, and knockdown of Pax3 during gastrulation has no effect on neural crest development (Basch et al., 2006).

The position of the E3MO containing cells in the dorsal neural tube and their maintenance of Pax7 expression suggests that they may represent either neural or neural crest progenitor cells. Given that they have low levels of Sox2 expression (Fig. 4A–4E), a known marker for neural progenitor cells (Graham et al., 2003), we speculate that they represent neural crest progenitors prior to the expression of neural crest specifier genes like *FoxD3*, *Sox10* and *Snail2*. A similar situation has been observed for Pax7 expressing cells in the olfactory epithelium. Pax7 is expressed in olfactory precursor cells, which are multipotent and can give rise to multiple olfactory cell types (Murdoch et al., 2010). Our results suggest that in the neural crest, Elk3 may be required for the Pax7-positive dorsal neural tube cells to

progress along the NC program; such that they subsequently upregulate NC cell specifiers enabling them to emigrate from the neural tube. Interestingly, we noted some cell death in the neural tube, which does not express detectable *Elk3* by in situ hybridization. This neural cell death could be a non-cell autonomous effect due to a role of *Elk3* in the mesenchyme adjacent to the neural tube (Fig. 1E'). *Elk3* is also known to be a downstream effector of FGF signaling, which is involved in neural development.

Our data show that loss of *Elk3* at HH4 leads to a severe reduction in migrating neural crest cells (Fig. 3, 5). One possible explanation for the abrogation of NC cell migration observed in *Elk3*-morphant embryos is that it may be a secondary consequence of the block to NC cell specification resulting in a failure to exit the neural tube and initiate migration. Consistent with this possibility, we observed numerous Pax7-positive cells retained in the dorsal neural tube of morphant, but not control embryos, at stages of active cranial NC migration (Fig. 5F, 5G). These Pax7+/Elk3-morphant cells apparently failed to migrate as the numbers of Pax7+ cells were much reduced in the periphery. Thus, we speculate that the lack of migration may be due to the maintenance of progenitor status (Pax7-positive precursor cells) that are unable to progress to definitive neural crest cells due to their failure to upregulate transcription factors like *FoxD3* and *Sox10*, which are required for NC cell specification and migration (Drerup et al., 2009; Stewart et al., 2006).

An alternative possibility is that *Elk3* may be directly required for the emigration of Pax7+ neural crest precursors cells. *Elk3* is expressed in migratory NC cells (Fig. 1E, 1E') consistent with a possible role in migration. However, *Elk3* expression levels are reduced in the dorsal neural tube just prior to EMT. It is possible that *Elk3* may regulate cell adhesion during NC cell migration in a similar manner to its function in mouse embryonic fibroblast migration (Buchwalter et al., 2005), where it acts as a transcriptional repressor. Thus, it would be interesting to test whether the loss of *Elk3* in the premigratory NC cell population leads to a dysregulation of adhesion molecules, which are tightly regulated during the process of EMT (Kerosuo and Bronner-Fraser, 2012). The finding that *Elk3* knockdown has a less severe, but still apparent, effect on NC cell migration when injected just prior to EMT (Fig. 3) seems consistent with a primary role in specification with an additional, but less penetrant role in migration.

Conclusions

In summary, our study reveals a novel function for the transcriptional regulator, *Elk3*, in neural crest development. The results place *Elk3* downstream of neural plate border genes and upstream of neural crest specifiers in the NC gene regulatory network (Betancur et al., 2010) and establish *Elk3* as a protein required for the progression of the NC program from progenitor to definitive neural crest cell. This research has allowed us to elaborate the NC-GRN and establish a new tier of regulation that may be critical for maintenance of neural crest “stemness.”

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank Laura Gammill and Meghan Adams for previous identification of *Elk3* and the Bronner lab for helpful discussions. This work was supported by NIH grant HD037105 to MEB, NIH minority supplement P01 HD037105 to CDR, and an Amgen summer fellowship and SURF fellowship to JLP.

References

- Acloque H, Wilkinson DG, Nieto MA. In situ hybridization analysis of chick embryos in whole-mount and tissue sections. *Methods in cell biology*. 2008; 87:169–185. [PubMed: 18485297]
- Adams MS, Gammill LS, Bronner-Fraser M. Discovery of transcription factors and other candidate regulators of neural crest development. *Dev Dyn*. 2008; 237:1021–1033. [PubMed: 18351660]
- Ayadi A, Suelves M, Dolle P, Wasylyk B. Net, an Ets ternary complex transcription factor, is expressed in sites of vasculogenesis, angiogenesis, and chondrogenesis during mouse development. *Mechanisms of development*. 2001a; 102:205–208. [PubMed: 11287193]
- Ayadi A, Zheng H, Sobieszczuk P, Buchwalter G, Moerman P, Alitalo K, Wasylyk B. Net-targeted mutant mice develop a vascular phenotype and up-regulate eg-1. *The EMBO journal*. 2001b; 20:5139–5152. [PubMed: 11566878]
- Basch ML, Bronner-Fraser M, Garcia-Castro MI. Specification of the neural crest occurs during gastrulation and requires Pax7. *Nature*. 2006; 441:218–222. [PubMed: 16688176]
- Betancur P, Bronner-Fraser M, Sauka-Spengler T. Assembling neural crest regulatory circuits into a gene regulatory network. *Annual review of cell and developmental biology*. 2010; 26:581–603.
- Bowes JB, Snyder KA, Segerdell E, Jarabek CJ, Azam K, Zorn AM, Vize PD. Xenbase: gene expression and improved integration. *Nucleic Acids Res*. 2010; 38:D607–D612. [PubMed: 19884130]
- Buchwalter G, Gross C, Wasylyk B. The ternary complex factor Net regulates cell migration through inhibition of PAI-1 expression. *Molecular and cellular biology*. 2005; 25:10853–10862. [PubMed: 16314510]
- Drerup CM, Wiora HM, Topczewski J, Morris JA. *Disc1* regulates *foxd3* and *sox10* expression, affecting neural crest migration and differentiation. *Development*. 2009; 136:2623–2632. [PubMed: 19570850]
- Gammill LS, Bronner-Fraser M. Genomic analysis of neural crest induction. *Development*. 2002; 129:5731–5741. [PubMed: 12421712]
- Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. *Neuron*. 2003; 39:749–765. [PubMed: 12948443]
- Kerosuo L, Bronner-Fraser M. What is bad in cancer is good in the embryo: importance of EMT in neural crest development. *Seminars in cell & developmental biology*. 2012; 23:320–332. [PubMed: 22430756]
- Krispin S, Nitzan E, Kalcheim C. The dorsal neural tube: a dynamic setting for cell fate decisions. *Developmental neurobiology*. 2010; 70:796–812. [PubMed: 20683859]
- Li B, Ni P, Zhu Q, Cao H, Xu H, Zhang S, Au C, Zhang Y. Growth inhibitory effect of the ternary complex factor Net on human pancreatic carcinoma cell lines. *The Tohoku journal of experimental medicine*. 2008; 216:139–147. [PubMed: 18832796]
- Mansouri A, Stoykova A, Torres M, Gruss P. Dysgenesis of cephalic neural crest derivatives in *Pax7*^{-/-} mutant mice. *Development*. 1996; 122:831–838. [PubMed: 8631261]
- Murdoch B, DelConte C, Garcia-Castro MI. Embryonic *Pax7*-expressing progenitors contribute multiple cell types to the postnatal olfactory epithelium. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010; 30:9523–9532. [PubMed: 20631180]
- Murdoch B, Delconte C, Garcia-Castro MI. *Pax7* lineage contributions to the Mammalian neural crest. *PLoS One*. 2012; 7:e41089. [PubMed: 22848431]
- Nakade K, Zheng H, Ganguli G, Buchwalter G, Gross C, Wasylyk B. The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling. *Molecular and cellular biology*. 2004; 24:1132–1142. [PubMed: 14729959]
- Nozaki M, Onishi Y, Kanno N, Ono Y, Fujimura Y. Molecular cloning of Elk-3, a new member of the Ets family expressed during mouse embryogenesis and analysis of its transcriptional repression activity. *DNA and cell biology*. 1996; 15:855–862. [PubMed: 8892757]
- Rogers CD, Jayasena CS, Nie S, Bronner ME. Neural crest specification: tissues, signals, and transcription factors. *Wiley Interdisciplinary Reviews: Developmental Biology*. 2012; 1:52–68.
- Sauka-Spengler T, Bronner-Fraser M. A gene regulatory network orchestrates neural crest formation. *Nat Rev Mol Cell Biol*. 2008; 9:557–568. [PubMed: 18523435]

- Sloan KA, Marquez HA, Li J, Cao Y, Hinds A, O'Hara CJ, Kathuria S, Ramirez MI, Williams MC, Kathuria H. Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines. *Carcinogenesis*. 2009; 30:1433–1442. [PubMed: 19483189]
- Stewart RA, Arduini BL, Berghmans S, George RE, Kanki JP, Henion PD, Look AT. Zebrafish foxd3 is selectively required for neural crest specification, migration and survival. *Dev Biol*. 2006; 292:174–188. [PubMed: 16499899]
- Voiculescu O, Papanayotou C, Stern CD. Spatially and temporally controlled electroporation of early chick embryos. *Nature protocols*. 2008; 3:419–426.
- Zheng H, Wasylyk C, Ayadi A, Abecassis J, Schalken JA, Rogatsch H, Wernert N, Maira SM, Multon MC, Wasylyk B. The transcription factor Net regulates the angiogenic switch. *Genes Dev*. 2003; 17:2283–2297. [PubMed: 12975317]

- *Elk3* is expressed in the neural folds prior to neural crest EMT, and in the migratory crest during early avian development.
- Elk3 is required for neural crest specification marked by *FoxD3* and *Sox10*.
- Loss of Elk3 leads to the maintenance of Pax7 positive, but FoxD3/Sox10 negative cells in the dorsal neural tube.
- Elk3 is required in the NC-GRN downstream of NC border genes and upstream of NC specifiers




Figure 1. Expression of *Elk3* during avian development

(A) Schematic diagram of the *Elk3* protein with the six functional domains (identified by color) and the amino acid sequence. (B–F) Whole mount in situ hybridization (WISH) of *Elk3* at stages HH4 (B), HH8–(C), HH9 (D), HH11 (D), and HH20 (F). *Elk3* is expressed in the developing head mesenchyme, neural folds and migratory neural crest cells, intersomitic vessels and the developing limb buds. (E') Section of HH11 embryo from (E). WISH of *Elk3* expression (top panel), immunohistochemistry of HNK1 (middle panel), and overlay (bottom panel) showing that *Elk3* expression overlaps with migratory cells. (G) Quantitative PCR showing the expression of the *Elk3* transcript compared with HH4 embryos and normalized with *GAPDH* expression. The Livak/ $\Delta\Delta Ct$ method was used for the quantitative analysis. Scale bars: 200 μm (B–F), 100 μm (C', E').




Figure 2. Elk3 is required for cranial NC specification

(A–E) Whole mount in situ hybridization of *FoxD3* (A–B) and *Sox10* (C–E) in embryos electroporated at HH4 with either the E3MO alone (A, C, 2.5–3mM, arrows show loss of expression) or the E3MO with Elk3-RFP DNA (B, D, 3mM and 3μg/μl). (E) Section of embryo fixed at HH9 showing WISH for *Sox10* expression (top panel) which is downregulated in the cells with E3MO (middle panel) and the overlay (bottom panel). (F, G) Immunohistochemistry of embryos electroporated at HH4 with ContMO on left and E3MO on right showing *Snail2* (downregulation on right side compared with control side) and *Pax7* protein expression. Dashed lines are sections of these embryos shown in F' and G'. (H, I) Sections of HH9 embryo electroporated with RFP on the left side and Elk3 over-expression

construct on the right side, whole mount immunohistochemistry for Snail2 (green, left panel) and Pax7 (green, right panel) was performed. Sections of these embryos are shown in H' and I' and overlay is below showing RFP from DNA constructs in red. 200 μm (A-D, F, G, H, I), 100 μm (E, F'-I').




Figure 3. Loss of Elk3 affects cranial NC development in a stage-dependent fashion
 (A–D) Whole mount in situ hybridization of *Sox10* (A–B) in embryos electroporated at stages HH5– HH8 with the E3MO on the right side (asterisks) and ContMO on the left side. E3MO affects neural crest development at all stages, but the severity declines with time and is not obvious by whole mount when electroporated at stage 8 (D). (E–G) Whole mount immunohistochemistry with antibodies to Pax7 (red) and HNK1 (blue) in embryos electroporated at stages HH5– HH8 with the E3MO on the right side and ContMO on the left side (Fitc, green). Similar effects are seen when E3MO is electroporated at stages HH5–6 as at earlier stages (see Fig. 2, 5). At HH7–8, the effects are less dramatic, but a delay in neural crest migration is still evident. (E'–G') Cryosections of embryos from E–G showing overlays

of Pax7/Fitc (top panel) and HNK1/Fitc (bottom panel). Scale bars: 200 μm (A–G), 100 μm (E'–G').




Figure 4. Loss of Elk3 does not affect neural or ectodermal development

(A, B) Whole mount in situ hybridization of *Sox2* and (C, D) immunohistochemistry showing no change in expression for *Sox2* and *Pax6* in embryos electroporated with the E3MO alone (A, B, right side) or with the ContMO and E3MO (C, D, ContMO is on left side and E3MO on right) at HH4. (E) Whole mount immunohistochemistry for *Sox2* using an embryo electroporated with Elk3 at HH4 showing no effect. (C'-E') Sections showing that loss and gain of Elk3 does not lead to a loss of neural tissue marked by *Sox2* (C', E') or dorsal neural tube and ectoderm marked by *Pax6* (D'). Scale bars: 200 μm (A-E), 100 μm (C'-E').




Figure 5. Knockdown of Elk3 severely effects cranial NC migration

(A–D) Whole mount in situ hybridization of *Sox10* (A, B) and *Snail2* (C, D) in embryos injected with the E3MO at HH4 showing a dose-dependent response (1.5mM and 3mM as indicated on figure). (E, F) Immunohistochemistry for HNK1 and Pax7 in HH9 embryos electroporated with ContMO on the left side and E3MO on the right side at HH4 (FITC in inset). (G) Section of an HH10 embryo immunostained for Pax7 (top panel) and overlaid with E3MO/FITC (bottom panel). Scale bars: 200 μ m (A–F), 100 μ m (G).